A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease

Liver Diseases Clinical Trial

Official title:

A Pharmacokinetic Study of Baricitinib in Subjects With Hepatic Dysfunction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01870388
• Other study ID #: 14600
• Secondary ID: I4V-MC-JAGC
• Status: Completed
• Phase: Phase 1
• First received: June 3, 2013
• Last updated: September 10, 2013
• Start date: June 2013
• Est. completion date: July 2013

Study information

• Verified date: September 2013
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to measure how much of the study drug called baricitinib gets into the blood stream and how long it takes the body to get rid of it. Healthy participants and those with liver disease may enroll. The study will last about 7 days for each participant, not including screening.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: July 2013
• Est. primary completion date: July 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria for ALL Participants:

• Male participants agree to use 2 reliable methods of birth control with female partners of child-bearing potential during the study and for at least 3 months following the last dose of study drug

• Women not of child-bearing potential due to surgical sterilization (at least 6 weeks after surgical bilateral oophorectomy with or without hysterectomy or at least 6 weeks after confirmed tubal occlusion/tubal ligation) confirmed by medical history, or menopause

• Menopausal women with spontaneous amenorrhea for at least 12 months, not induced by a medical condition and by medications and have a follicle-stimulating hormone (FSH) level greater than 40 milli-international units per milliliter (mIU/mL) (unless the participant is taking hormone replacement therapy [HRT])

• Have a body mass index of 18.5 to 40.0 kilograms per square meter (kg/m^2) inclusive at the time of screening

Additional Inclusion Criteria for Healthy Participants:

• Are overtly healthy participants, have normal hepatic function and have stable chronic medical conditions

• Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator

Additional Inclusion Criteria for Hepatically Impaired Participants:

• Participants with hepatic impairment classified as Child-Pugh score A or B (mild [Group 3, if enrolled] or moderate [Group 2] impairment, respectively). Must have a diagnosis of chronic hepatic impairment (greater than 6 months), with no clinically significant changes within 90 days prior to study drug administration (Day 1). Participants may have mild stable baseline medical conditions for which neither the condition nor treatments received would negatively impact the health of the participant or study conduct

• Clinical laboratory test results with deviations that are judged by the investigator to be compatible with the hepatic impairment of the participant, or of no additional clinical significance for this study

Exclusion Criteria for ALL Participants:

• Have received, within the last 30 days, an investigational product as part of a clinical trial, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study

• Persons who have previously completed or withdrawn from study investigating baricitinib, and have previously received the investigational product

• Women with a positive pregnancy test or who are lactating

• Have a current or recent history (less than 30 days prior to screening and/or less than 45 days prior to admission to the clinical research unit) of a clinically significant bacterial, fungal, parasitic, viral (excluding rhinopharyngitis), or mycobacterial infection

• Have had symptomatic herpes zoster or herpes simplex infection within 90 days prior to the first dose

• Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies

• Have been exposed to a live vaccine within 12 weeks prior to the first dose or expected to need/receive a live vaccine (including herpes zoster vaccination) during the course of the study

Additional Exclusion Criteria for Healthy Participants:

• Show evidence of acute or chronic liver disease

• Show evidence of hepatitis B and/or positive hepatitis B and/or positive hepatitis B surface antigen

• Show evidence of hepatitis C and/or positive hepatitis C antibody

• Intend to use over-the-counter or prescription medication and/or herbal supplements within 14 days prior to dosing and during the study

Additional Exclusion Criteria for Liver Impaired Participants:

• Have creatinine clearance less than or equal to 50 milli-liter per minute (mL/min) using the Cockcroft and Gault formula

• Show evidence of spontaneous bacterial peritonitis within 6 month of dosing

• Have had variceal bleeding within 3 months of check in

• Show evidence of severe hyponatremia (sodium less than 120 millimolar per liter (mmol/L)

• Have severe encephalopathy(Grade 3 to 4)

• Have moderate to severe ascites (moderately hepatically impaired participants only)

• Show presence of a portal shunt

• Have hemoglobin less than 9.0 grams per deciliter (g/dL)

• Have serum bilirubin greater than 15 milligrams per deciliter (mg/dL)

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Hepatic Insufficiency
• Liver Diseases

Intervention

Drug:
• Baricitinib
Administered orally

Locations

Country	Name	City	State
United States	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Miami	Florida
United States	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Orlando	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3009104		Predose up to 48 hours post dose	No
Primary	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Zero to Infinity [AUC(0-8)] of LY3009104		Predose up to 48 hours post dose	No